Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-19
    E.g., 2018-08-19

Archive Search

Pages

662 results
12:19 PM, Aug 10, 2018  |  BC Week In Review | Clinical News  |  Regulatory

FDA approves Kyowa's Poteligeo for CTCL

FDA approved Poteligeo mogamulizumab-kpkc from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) to treat the two most common forms …
disclose the drug's price. The drug is under EMA review, and is approved in Japan. Kyowa Hakko Kirin
11:31 AM, Aug 08, 2018  |  BC Extra | Company News

FDA approves Kyowa's Poteligeo for CTCL

FDA approved Poteligeo mogamulizumab-kpkc from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) to treat the two most common forms …
10:53 AM, Aug 03, 2018  |  BC Week In Review | Company News  |  Deals

Kyowa, Ultragenyx sell Priority Review voucher for $80.6M

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) revealed that it and partner Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) sold a rare …
67.5 million to $350 million (see “Voucher Equilibrium” ). Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Novato, Calif.  Kyowa Hakko Kirin
10:06 AM, Aug 03, 2018  |  BC Week In Review | Clinical News  |  Regulatory

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

from Fujifilm Kyowa Kirin Biologics Co. Ltd., a JV between Fujifilm Holdings Corp. (Tokyo:4901) and Kyowa Hakko Kirin
10:45 AM, Jul 31, 2018  |  BC Extra | Company News

Kyowa, Ultragenyx sell Priority Review voucher for $80.6M

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) revealed that it and partner Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) sold a rare …
3:08 PM, Jul 27, 2018  |  BC Extra | Company News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

from Fujifilm Kyowa Kirin Biologics Co. Ltd., a JV between Fujifilm Holdings Corp. (Tokyo:4901) and Kyowa Hakko Kirin
1:06 PM, Jul 27, 2018  |  BioCentury | Finance

Earnings on deck

C) $3.67 $3.73 -2% Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) (A) 7/31 Post NA ¥184.39 NA Kyowa Hakko Kirin
8:05 PM, Jun 29, 2018  |  BioCentury | Finance

Hidden in the rough

Inc. (NASDAQ:AMGN) EC approves Kineret anakinra to treat Still's disease Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) / Kyowa Hakko Kirin
8:04 PM, Jun 29, 2018  |  BioCentury | Finance

Eyes on launches

PKU) in patients who have uncontrolled blood phenylalanine levels on current treatment. Ultragenyx and partner Kyowa Hakko Kirin
Care Inc., Boston, Mass. Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Ionis Pharmaceuticals Inc. (NASDAQ:IONS), Carlsbad, Calif. Kyowa Hakko Kirin
7:24 AM, Jun 29, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Ultragenyx's Crysvita meets in Phase III for pediatric XLH

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) said Crysvita burosumab-twza (KRN23, UX023) met the …
Kyowa partnered in 2013 to develop and commercialize Crysvita. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Novato, Calif.  Kyowa Hakko Kirin

Pages